GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Authors
Keywords
-
Journal
Nature Reviews Endocrinology
Volume 8, Issue 12, Pages 728-742
Publisher
Springer Nature
Online
2012-09-04
DOI
10.1038/nrendo.2012.140
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tu1502 Longitudinal Monitoring of Lipase and Amylase in Adults With Type 2 Diabetes and Obesity: Evidence From Two Phase 3 Randomized Clinical Trials With the Once-Daily GLP-1 Analog Liraglutide
- (2015) William Steinberg et al. GASTROENTEROLOGY
- Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes
- (2013) John B. Buse et al. ANNALS OF INTERNAL MEDICINE
- Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets
- (2012) J. H. DeVries et al. DIABETES CARE
- The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients
- (2011) Anne Flint et al. ADVANCES IN THERAPY
- Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states
- (2011) Sarah Farr et al. CURRENT OPINION IN LIPIDOLOGY
- Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
- (2011) M. A. Nauck et al. DIABETES
- Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual -Cell Function
- (2011) U. Kielgast et al. DIABETES CARE
- Effects of Exenatide on Measures of -Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
- (2011) M. C. Bunck et al. DIABETES CARE
- LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects
- (2011) P. Barrington et al. DIABETES OBESITY & METABOLISM
- The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study
- (2011) G. E. Umpierrez et al. DIABETES OBESITY & METABOLISM
- A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
- (2011) P. Barrington et al. DIABETES OBESITY & METABOLISM
- Achieving a clinically relevant composite outcome of an HbA1c of
- (2011) B. Zinman et al. DIABETES OBESITY & METABOLISM
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- A thorough QT study to evaluate the effects of singledose exenatide 10 μg on cardiac repolarization in healthy subjects
- (2011) H. Linnebjerg et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Provides Neuroprotection in Mice Transient Focal Cerebral Ischemia
- (2011) Shinichiro Teramoto et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide
- (2011) Laszlo Hegedüs et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials
- (2011) John B. Buse et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease
- (2011) P. L. McClean et al. JOURNAL OF NEUROSCIENCE
- GLP-1 analogues and insulin: sound the wedding bells?
- (2011) Michael A. Nauck et al. Nature Reviews Endocrinology
- Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
- (2010) Anne Gill et al. Cardiovascular Diabetology
- DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease
- (2010) Philip A. Read et al. Circulation-Cardiovascular Imaging
- A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus
- (2010) Eduard Montanya et al. CLINICAL THERAPEUTICS
- The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
- (2010) K. J. Hare et al. DIABETES
- Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: A proof-of-concept study
- (2010) S. Arnolds et al. DIABETES CARE
- Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis
- (2010) R. Garg et al. DIABETES CARE
- Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
- (2010) R. E. Ratner et al. DIABETIC MEDICINE
- Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
- (2010) Lotte Bjerre Knudsen et al. ENDOCRINOLOGY
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
- (2010) Michaela Diamant et al. LANCET
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Individualised incretin-based treatment for type 2 diabetes
- (2010) Michael A Nauck et al. LANCET
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
- (2010) Richard E Pratley et al. LANCET
- Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
- (2010) Mary Parks et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
- (2010) Ulrich Werner et al. REGULATORY PEPTIDES
- Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus
- (2009) Yutaka Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Age-Dependent Decline in -Cell Proliferation Restricts the Capacity of -Cell Regeneration in Mice
- (2009) S.-I. Tschen et al. DIABETES
- GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
- (2009) M. H. Noyan-Ashraf et al. DIABETES
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing
- (2009) J. Rosenstock et al. DIABETES CARE
- Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study
- (2009) R. A. Noel et al. DIABETES CARE
- Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
- (2009) M. A. Bush et al. DIABETES OBESITY & METABOLISM
- Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes
- (2009) K. Kaku et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- Absence of QTc Prolongation in a Thorough QT Study With Subcutaneous Liraglutide, a Once-Daily Human GLP-1 Analog for Treatment of Type 2 Diabetes
- (2009) Dhruba J. Chatterjee et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Incretin-based therapies for type 2 diabetes mellitus
- (2009) Julie A. Lovshin et al. Nature Reviews Endocrinology
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
- (2008) Ralph A. DeFronzo et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
- (2008) M. Nauck et al. DIABETES CARE
- Combined thiazolidinedione–metformin treatment synergistically improves insulin signalling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinase, atypical protein kinase C and protein kinase B/Akt in human diabetic muscle
- (2008) N. Temofonte et al. DIABETOLOGIA
- Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes
- (2008) Jessica E. Matthews et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease
- (2008) Alexander Harkavyi et al. Journal of Neuroinflammation
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- Treatment of type 2 diabetes with incretin-based therapies
- (2008) Sten Madsbad LANCET
- Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
- (2008) Alan Garber et al. LANCET
- Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
- (2008) Helle Linnebjerg et al. REGULATORY PEPTIDES
- Hyperamylasaemia and/or hyperlipasaemia: Incidence and underlying causes in hospitalized patients with non-pancreatic diseases
- (2008) Paul Georg Lankisch et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart
- (2007) David P. Sonne et al. REGULATORY PEPTIDES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More